PMID,Study Type,Disease Name,External Validation,Date Range in the Development Set,Date Range in the Validation Set,Median Follow-up Time (Years) and IQR,Mean Follow-up Time (Years) and Standard Error,Data Sources,Sample Characteristics,Number of Cases in the Development Set,Number of Controls in the Development Set,Number of Cases in the Validation Set,Number of Controls in the Validation Set,Number of Female Participants (Development),Number of Female Participants (Validation),Number of Male Participants (Development),Number of Male Participants (Validation),Age Range (Development),Age Range (Validation),Average Age and Standard Deviation (Development),Average Age and Standard Deviation (Validation),Median Age (Development) and IQR,Median Age (Validation) and IQR,Racial/Ethnic Composition (Development),Racial/Ethnic Composition (Validation)
37842633,Prospective study,Depression,No,2013–2018,N/A,N/A,5 years (SD: NA),China Health and Retirement Longitudinal Study (CHARLS) dataset,"Age ≥45 years, includes chronic diseases (e.g., hypertension, dyslipidemia, diabetes), smoking, drinking, social participation, economic and environmental factors",1255,2632,N/A,N/A,2055,N/A,1832,N/A,≥45 years,N/A,62.34 years (SD: NA),N/A,N/A,N/A,Predominantly Chinese (Han and possibly minority groups),N/A
40205377,Retrospective study,Depression,No,2011,2011,N/A,N/A,China Health and Retirement Longitudinal Study (CHARLS) 2011 dataset,Rural elderly individuals living alone,633,588,N/A,N/A,817,N/A,404,N/A,≥60 years,≥60 years,71.9 years (SD = 7.7),71.9 years (SD = 7.7),N/A,N/A,N/A,N/A
36509405,Retrospective study,Asthma,No,2003-2020,N/A,N/A,0.5 years (SD: NA),OptumLabs Data Warehouse (OLDW),"Patients with persistent asthma who received asthma biologic therapy (benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab)",552,1895,N/A,N/A,1505,N/A,942,N/A,0-11 to 65+ years,N/A,47.1 years (SD: 17.1),N/A,N/A,N/A,"White: 74.13%, Hispanic: 8.75%, Black: 9.28%, Asian: 3.64%, Unknown: 4.21%",N/A
34841728,Prospective study,Childhood asthma,Yes,N/A,N/A,N/A,10 years (SD: NA),Isle of Wight Birth Cohort (IOWBC) for development; Manchester Asthma and Allergy Study (MAAS) for validation,General population-based cohort (development); general population and high-risk subgroups with parental allergic disease (validation),201,1167,132,1038,N/A,N/A,N/A,N/A,Birth to 10 years,8 to 11 years,N/A,N/A,N/A,N/A,Predominantly Caucasian,Predominantly Caucasian
35177746,Prospective study,chronic kidney disease,No,2006–2018,N/A,N/A,Up to 13 years (SD: NA),"Tianjin Medical University Chronic Disease Cohort, UK Biobank (for genetic data), UCSC Genomic Bioinformatics Database","No CKD at baseline, higher incidence of type 2 diabetes and hyperuricemia in CKD group, teachers and government employees, no family history of inherited diseases, no nephrotoxic drug usage",116,232,N/A,N/A,88,N/A,260,N/A,N/A,N/A,63.27 years (SD = 10.09),N/A,N/A,N/A,N/A,N/A
36959840,Retrospective study,Chronic Kidney Disease (CKD),No,N/A,N/A,N/A,N/A,UCI repository CKD dataset,CKD patients and healthy individuals,250,150,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
38186582,Prospective study,Chronic Obstructive Pulmonary Disease (COPD),Yes,2014–2020,2014–2020,N/A,3.59 years,COPD Surveillance in China,"Subjects aged ≥40 years without airflow limitation, with assessed risk factors (smoking, indoor biomass/coal exposure, workplace dust/chemical exposure, history of emphysema, coronary heart disease, or hypertension)",235,3291,30,431,2039,N/A,1487,N/A,≥40 years,≥40 years,54.5 years (SD: 9.3),N/A,N/A,N/A,Chinese,Chinese
33664570,Cross-sectional study,Chronic Obstructive Pulmonary Disease (COPD),No,2018,N/A,N/A,N/A,Natural Population Cohort Study in Northwest China (SQ2017YFSF090013) and its sub-project Study on Cohort Construction and Health Follow-up of Xinjiang Multi-ethnic Natural Population (2017YFC0907203),"Rural population with smoking (14.2%), passive smoking (7.9%), coal/biofuel use (95.5%), low socioeconomic status, and some with tuberculosis history",394,2855,N/A,N/A,N/A,N/A,N/A,N/A,35–79 years,N/A,52.8 years (SD = 9.4),N/A,N/A,N/A,Multi-ethnic population in Xinjiang,N/A
35672659,Retrospective study,Myocardial infarction (MI),No,2011–2020,N/A,N/A,N/A,West China Hospital of Sichuan University (hospital medical records),MI group: Diagnosed with myocardial infarction; Control group: No myocardial infarction,14446,220369,N/A,N/A,92189,N/A,142626,N/A,MI: –92.7 years; Control: –96.0 years,N/A,MI: 65.9 years (SD = 13.4); Control: 62.4 years (SD = 16.8),N/A,N/A,N/A,N/A,N/A
34737789,Retrospective study,Acute myocardial infarction (AMI),No,N/A,N/A,N/A,N/A,Cooperative Chinese medicine company,"AMI patients; excluded images with severe peeling, scars, or unnatural palm positions",N/A,N/A,N/A,N/A,119,N/A,182,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
35059311,Prospective study,Lung cancer,No,2013-2019,N/A,2.95 years (IQR: 1.71–4.83),N/A,Cancer Screening Program in Urban China (CanSPUC) conducted in Henan Province,"Non-smokers (excluding former smokers), aged 40–74, no prior lung cancer",344,214420,N/A,N/A,151838,N/A,62926,N/A,40–74 years,N/A,55.19 years (SD: 8.78),N/A,N/A,N/A,"Han: 98.29%, Others: 1.71%",N/A
29621362,Prospective study,Invasive breast cancer,No,1996-2014,N/A,5.2 years (IQR: 2.4–11.1),N/A,Kaiser Permanente Washington Breast Cancer Surveillance Consortium (BCSC) registry,"Women without prior invasive breast cancer or ductal carcinoma in situ, aged 40–73 years, attending routine mammography screening",2699,129440,N/A,N/A,132139,N/A,0,N/A,40–73 years,N/A,N/A,N/A,50 years (IQR: 44–58),N/A,"White: 80.4%, Asian: 8.8%, Black: 3.9%, More than one race: 2.7%, Other: 2.6%, Unknown: 1.5%; Non-Hispanic: 93.7%, Hispanic: 5.0%, Unknown Hispanic: 1.4%",N/A
29574637,Retrospective study,Contralateral breast cancer (CBC),Yes,1995–2009 (BCSC); NA (SEER),1990–2016 (JH); 1983–2014 (MDA),JH Cases: 6 years; JH Controls: 7.4 years; MDA Cases: 4.2 years; MDA Controls: 4.8 years; IQR: NA,JH Cases: 6.4 years; JH Controls: 8 years; MDA Cases: 5.1 years; MDA Controls: 5.8 years; SD: NA,"Breast Cancer Surveillance Consortium (BCSC), Surveillance, Epidemiology, and End Results (SEER), Johns Hopkins University (JH), University of Texas MD Anderson Cancer Center (MDA)","Women aged 18–88 years with unilateral invasive breast cancer or DCIS, excluding those with CPM or CBC within 6 months",BCSC: 1921; SEER: 19835,BCSC: 75825; SEER: 804933,JH: 117; MDA: 111,JH: 5918; MDA: 5074,BCSC: 77746; SEER: 824768,JH: 6035; MDA: 5185,0,0,18–88 years,18–88 years,N/A,N/A,N/A,N/A,N/A,N/A
37511678,Retrospective study,Colorectal Cancer (CRC),No,SOCCS: 1999–ongoing; LABSS: 2017–ongoing,N/A,N/A,N/A,Study of Colorectal Cancer in Scotland (SOCCS); Lothian Bowel Symptoms Study (LABSS),"Participants with gastrointestinal symptoms (e.g., changes in bowel habits, rectal bleeding, weight loss, anaemia, abdominal pain)",1686,963,N/A,N/A,1267,N/A,1382,N/A,"≥16 years (SOCCS), ≥18 years (LABSS)",N/A,N/A,N/A,65.42 years (IQR: 56.00–73.50),N/A,Primarily European descent,N/A
33390155,Prospective study,Colorectal cancer,Yes,1992–2010,1992–2010,15.4 years (IQR: 13.2–16.9),N/A,EPIC (European Prospective Investigation into Cancer and Nutrition),"Excluded prevalent cancer, diabetes, myocardial infarction, stroke; included smokers (23.5% current, 27.4% former in development set)",3572,251910,1054,73349,172381,45144,83101,29259,19.5–70.0 years,19.9–70.0 years,51.4 years (SD: 9.7),49.7 years (SD: 9.6),N/A,N/A,N/A,N/A
36493335,Retrospective study,Prostate cancer (PCa),Yes,1993–2017,2006–2010,N/A,N/A,"UK Genetic Prostate Cancer Study (UKGPCS), UK Biobank","Development: Probands with histologically confirmed PCa (50% diagnosed by symptoms, 24% by PSA screening, 26% unknown); 30% with PCa in first- or second-degree relatives. Validation: Participants free of cancer at recruitment (except nonmelanoma skin cancers).",16633,4319,"3,456 (5-year follow-up); 7,624 (10-year follow-up)","167,394 (5-year follow-up); 163,226 (10-year follow-up)",N/A,0,20952,170850,N/A,N/A,N/A,N/A,N/A,N/A,European ancestry,White British
35875103,Retrospective study,Prostate cancer (PCa),No,2013-2021,N/A,N/A,N/A,"Electronic medical records, First Hospital of Jilin University","Male patients undergoing prostate biopsy, tPSA >4 ng/ml, abnormal DRE, or imaging findings",302,249,N/A,N/A,0,N/A,551,N/A,≥18 years,N/A,N/A,N/A,N/A,N/A,N/A,N/A
33669642,Retrospective study,Gastric cancer (GC),No,2011-2014,1996–1997,N/A,N/A,"National Cancer Center, Korea; 1000 Genome Project phase 3 East Asian Ancestry (EAS)","GC cases (histologically confirmed), healthy controls; H. pylori infection, lifestyle factors (smoking, alcohol, diet)",450,1136,450,1136,750,750,836,836,N/A,N/A,Cases: 55.4 years (SD = 10.7); Controls: 52.1 years (SD = 8.5),N/A,N/A,N/A,Korean/East Asian,Korean
33223755,Prospective study,Gastric cancer,No,2015-2017,N/A,N/A,3.47 years (SD: NA),"Seven study sites in China (Cixian, Linzhou, Wuwei, Changsha, Harbin, Luoshan, Sheyang), with risk assessment in Changsha, Harbin, Luoshan, and Sheyang; linked to cancer registry and death surveillance systems","Aged 40–69 years, no history of cancer, no endoscopic examination in past 3 years, assessed for smoking, alcohol consumption, dietary habits, family history of upper gastrointestinal cancer, and gastric disease history",131,89783,N/A,N/A,49211,N/A,40703,N/A,40–69 years,N/A,53.83 years (SD: 8.04),N/A,N/A,N/A,N/A,N/A
36568745,Prospective study,Liver cancer,No,2006–2010,N/A,N/A,8.05 years (SD: NA),UK Biobank,"Participants with complete data on liver cancer outcome and risk factors, excluding those with baseline cancer diagnosis; includes various conditions such as smoking, alcohol use, diabetes, viral hepatitis, non-viral liver diseases, high cholesterol, cardiovascular disease, and family history of cancer",197,251445,N/A,N/A,135025,N/A,116617,N/A,37–73 years,N/A,56.8 years (SD: NA),N/A,50–59 years (IQR: 45–50 to 60–65),N/A,"White: 94.50%, Others: 5.23%, Unknown: 0.27%",N/A
39350987,Retrospective study,Hepatocellular carcinoma (HCC),Yes,2021-2022,2023,N/A,N/A,"The Second Hospital & Clinical Medical School, Lanzhou University","Patients with HCC or cirrhosis; excluded if on anticoagulation therapy, had HCC treatments, or had other tumors",190,195,83,82,94,47,288,118,47–59 years,47–59 years,N/A,N/A,53 years (IQR: 47–59),53 years (IQR: 48–58),N/A,N/A
36772237,Retrospective secondary data analysis,Coronary artery disease (CAD),No,N/A,N/A,N/A,N/A,Publicly available dataset,"Participants with smoking, hypertension, stroke, diabetes, and blood pressure medication use","556 (original), 3099 (SMOTE)","3099 (original), 3099 (SMOTE)",N/A,N/A,"2033 (original), 2805 (SMOTE)",N/A,"1622 (original), 3393 (SMOTE)",N/A,32–70 years,N/A,"49.5 years (SD: 8.56) (original), 51.5 years (SD: 8.34) (SMOTE)",N/A,N/A,N/A,N/A,N/A
39553308,Retrospective study,Coronary artery disease (CAD),No,N/A,N/A,N/A,N/A,"GEO database (GSE113079, GSE59421)",Patients with coronary artery disease (CAD),93,48,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
35983181,Retrospective study,Carotid atherosclerosis (CAS),Yes,2020,2015,N/A,N/A,"Electronic medical record system of Zhenhai Lianhua Hospital, Ningbo, China","Adults undergoing health checkups with conditions such as diabetes mellitus, hypertension, smoking history, and drinking history",3813,757,2039,752,1560,888,3010,1903,19–93 years,N/A,60.35 years (SD = 14.29),59.90 years (SD = 13.36),N/A,N/A,N/A,N/A
33936038,Cross-sectional study,Atherosclerosis in systemic lupus erythematosus (SLE),No,2019,N/A,N/A,N/A,"Chinese SLE Treatment and Research Group (CSTAR) registry, Peking Union Medical College Hospital","SLE patients, age >18 years, no active infection/tumor/severe SLE/CVD before SLE, using medications (e.g., statins, corticosteroids), some smokers, postmenopausal females, long disease duration, organ damage",20,47,N/A,N/A,63,N/A,4,N/A,N/A,N/A,N/A,N/A,42.7 years (IQR: 36.6–51.2),N/A,100% Chinese,N/A
36581881,Retrospective and Prospective,Sepsis,Yes,MIMIC-III: 2001–2012; HDRJH: 2011–2019,HDRJH: 2011–2019; Real-world: 2021,N/A,N/A,"MIMIC-III (Beth Israel Deaconess Medical Center, USA), Historical Database of Ruijin Hospital (HDRJH, China), Real-world data from Ruijin Hospital ICU (China)",ICU patients; sepsis (infection + SOFA score) or non-sepsis; some received antibiotics or mechanical ventilation,1201,6143,HDRJH: 144; Real-world: 22,HDRJH: 309; Real-world: 46,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
34255071,Prospective study,Second Primary Lung Cancer (SPLC),Yes,1993–2017,N/A,2.2 years (IQR: 0.2–2.6),N/A,"Multiethnic Cohort (MEC), Surveillance, Epidemiology, and End Results (SEER) registries, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), National Lung Screening Trial (NLST)",Ever-smokers with initial primary lung cancer (IPLC) diagnosis,145,6180,PLCO: 101; NLST: 93,PLCO: 2862; NLST: 2751,2529,PLCO: 1132; NLST: 1202,3796,PLCO: 1831; NLST: 1642,<55–≥80 years,PLCO: 55–≥80 years; NLST: 55–≥80 years,74.2 years (SD: 8.2),PLCO: 71.5 years (SD: 6.4); NLST: 68.4 years (SD: 6.1),N/A,N/A,"White: 25.2%, Japanese American: 21.5%, African American: 27.4%, Latino: 13.0%, Native Hawaiian: 8.4%, Others: 4.5%","PLCO: White: 88.4%, Asian: 2.4%, African American: 7.0%, Latino: 1.3%, Others: 1.0%; NLST: White: 90.6%, Asian: 1.6%, African American: 5.0%, Latino: 1.2%, Others: 1.6%"
33659912,Retrospective study,Sepsis,No,2000–2016,N/A,N/A,N/A,Cerner Health Facts database,Hospitalized adult patients (≥18 years) with proven or suspected infection and two or more SIRS criteria for sepsis cases,52802,126041,N/A,N/A,91459,N/A,87384,N/A,18–100 years,N/A,N/A,N/A,N/A,N/A,"African American: 17.8% (11,084 cases + 20,556 controls), Asian: 1.5% (1,085 cases + 1,627 controls), Caucasian: 72.7% (35,059 cases + 95,657 controls), Others/unknown: 7.8% (5,574 cases + 8,201 controls)",N/A
39076472,Retrospective study,Heart Failure (HF),No,N/A,N/A,N/A,N/A,Taiwan’s National Health Insurance Research Database (NHIRD),"Patients with HF diagnoses (experimental group) and non-HF participants (control group), matched for sex and age",8500,21786,N/A,N/A,16287,N/A,13765,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
39611013,Retrospective study,Acute Ischemic Stroke (AIS),No,2017-2021,N/A,N/A,N/A,Liuzhou Traditional Chinese Medicine Hospital (stroke green channel timing control system and electronic medical record system),"Patients with AIS, some with history of hypertension, cerebral infarction, cerebral artery occlusion, or carotid atherosclerosis",114,409,N/A,N/A,186,N/A,337,N/A,N/A,N/A,N/A,N/A,68 years (IQR: 59–76),N/A,N/A,N/A
34860663,Retrospective study,Stroke,No,2011–2015,N/A,N/A,N/A,National Health and Nutrition Examination Survey (NHANES),"Participants with and without stroke; no specific disease background, surgeries, treatments, or conditions like pregnancy or smoking explicitly mentioned",608,3578,N/A,N/A,190,N/A,220,N/A,N/A,N/A,N/A,N/A,51 years (IQR: NA),N/A,N/A,N/A
37970129,Retrospective study,Gestational diabetes mellitus (GDM),Yes,2020-2022,N/A,N/A,N/A,N/A,Pregnant women,197,209,N/A,N/A,406,N/A,0,N/A,22–43 years,N/A,31.17 years (SD: 4.02),N/A,N/A,N/A,N/A,N/A
36456970,Retrospective study,Gestational diabetes mellitus (GDM),No,2019-2021,N/A,N/A,N/A,First Affiliated Hospital of Jinan University and Jiangmen Maternity and Child Health Care Hospital,Pregnant women with singleton pregnancy,Basic: 1294; Extended: 910,Basic: 1601; Extended: 1206,N/A,N/A,Basic: 2895; Extended: 2116,N/A,0,N/A,N/A,N/A,N/A,N/A,Basic Training: 30.0 years (IQR: 27.0–32.0); Basic Validation: 30.0 years (IQR: 27.0–32.0); Extended Training: 30.0 years (IQR: 27.0–32.0); Extended Validation: 29.0 years (IQR: 27.0–32.0),N/A,N/A,N/A
34233656,Retrospective study,Alzheimer’s Disease (AD),Yes,2018-2019,2018-2019,N/A,N/A,Medical records from People’s Hospital of Xinjiang Uygur Autonomous Region,"Elderly patients (≥60 years old), some with AD, others without; health conditions include midlife hypertension, diabetes, herpesvirus infection, stroke, traumatic brain injury, depression; lifestyle factors include smoking, exercise, diet, alcohol consumption",416,408,139,136,281,107,543,168,N/A,N/A,66.82 years (SD = 4.01),66.94 years (SD = 4.23),N/A,N/A,N/A,N/A
32324812,Retrospective study,Alzheimer’s Disease (AD),No,N/A,N/A,N/A,N/A,National Institute on Aging—Late-Onset Alzheimer’s Disease Family Study: Genome-Wide Association Study for Susceptibility Loci (phs000168.v2.p2) from the National Center for Biotechnology Information (NCBI) through the Genotypes and Phenotypes database (dbGaP),"Cases: Diagnosed with Definite AD by neuropathological criteria or Probable AD by NINCDS-ADRDA criteria, age at diagnosis ≥ 60 years. Controls: No cognitive deterioration or memory loss, no history of psychiatric or neurological disorders.",813,1017,N/A,N/A,N/A,N/A,N/A,N/A,≥ 60 years,N/A,N/A,N/A,N/A,N/A,European-American,N/A
35365675,Retrospective study,Parkinson’s disease (PD),Yes,N/A,N/A,N/A,N/A,AMP PD Knowledge Platform (PPMI and PDBP datasets),"Unmedicated PD cases within 1 year of diagnosis (PPMI), PD cases within 5 years of diagnosis regardless of medication status (PDBP), controls unaffected by neurologic diseases",N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,"PPMI Case: 61.75 years (SD: 9.69), Control: 60.61 years (SD: 10.43)","PDBP Case: 64.59 years (SD: 8.99), Control: 62.87 years (SD: 10.96)",N/A,N/A,Primarily European ancestry,Primarily European ancestry
34745218,Retrospective study,Parkinson's disease,No,N/A,N/A,N/A,N/A,Parkinson’s Progression Marker Initiative (PPMI) dataset,N/A,296,140,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
34528757,Retrospective study,Heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF),No,2002–2006,N/A,N/A,N/A,"VA Corporate Data Warehouse (CDW), linked to Centers for Medicaid and Medicare Services (CMS) and National Death Index (NDI) databases","Patients with at least one primary care visit at a VA facility, at least one outpatient lipid result between 2002 and 2007, and a blood pressure measurement within 30 days of lipid testing; excluded individuals with severe comorbidities (cancer, dialysis, major mental health disorder), non-white or non-black race, heart failure before or within 30 days of baseline, or death within 30 days of baseline",HFpEF: 52679; HFrEF: 71463,1361773,N/A,N/A,36573,N/A,1319113,N/A,40–80 years,N/A,White men: 63.6 years (SD: 9.7); Black men: 57.3 years (SD: 10.3); White women: 56.5 years (SD: 11.4); Black women: 49.3 years (SD: 7.4),N/A,N/A,N/A,"White: 1,179,286 (86.6%); Black: 183,327 (13.4%); Hispanic or Latino: 57,846 (4.2%)",N/A
35141294,Retrospective study,Uncontrolled hypertension,Yes,2018,N/A,N/A,N/A,"Community hypertension clinics in 5 communities in Guangzhou and Dongguan, China",Patients with a history of hypertension receiving antihypertensive medicines,452,587,N/A,N/A,470,N/A,549,N/A,N/A,N/A,61 years (SD = 13),N/A,N/A,N/A,N/A,N/A
35896590,Prospective study,Hypertension,No,N/A,N/A,5.8 years (IQR: NA),N/A,"Alberta’s Tomorrow Project (ATP) cohort data, linked with Alberta’s administrative health data","Participants aged 35–69 years, without any history of cancer (other than non-melanoma skin cancer), free of hypertension at baseline",416,"11,817",N/A,N/A,"8,396",N/A,"3,837",N/A,35–70 years,N/A,50.99 years (SD: 0.07),N/A,N/A,N/A,"Aboriginal: 0.37%, Asian: 4.51%, White: 92.21%, Latin American Hispanic: 0.89%, Black: 0.53%, Other: 1.49%",N/A